686 related articles for article (PubMed ID: 12417881)
1. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis.
Kopp MV; Brauburger J; Riedinger F; Beischer D; Ihorst G; Kamin W; Zielen S; Bez ; Friedrichs F; Von Berg A; Gerhold K; Hamelmann E; Hultsch ; Kuehr J
J Allergy Clin Immunol; 2002 Nov; 110(5):728-35. PubMed ID: 12417881
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects.
Kopp MV; Stenglein S; Kamin W; Friedrichs F; von Berg A; Zielen S; Hamelmann E; Wahn U; Kuehr J
Pediatr Allergy Immunol; 2007 Sep; 18(6):523-7. PubMed ID: 17680911
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis.
Kuehr J; Brauburger J; Zielen S; Schauer U; Kamin W; Von Berg A; Leupold W; Bergmann KC; Rolinck-Werninghaus C; Gräve M; Hultsch T; Wahn U
J Allergy Clin Immunol; 2002 Feb; 109(2):274-80. PubMed ID: 11842297
[TBL] [Abstract][Full Text] [Related]
4. Urinary leukotriene E4 levels in children with allergic rhinitis treated with specific immunotherapy and anti-IgE (Omalizumab).
Kopp MV; Mayatepek E; Engels E; Brauburger J; Riedinger F; Ihorst G; Wahn U; Kuehr J
Pediatr Allergy Immunol; 2003 Oct; 14(5):401-4. PubMed ID: 14641611
[TBL] [Abstract][Full Text] [Related]
5. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children.
Rolinck-Werninghaus C; Hamelmann E; Keil T; Kulig M; Koetz K; Gerstner B; Kuehr J; Zielen S; Schauer U; Kamin W; Von Berg A; Hammermann J; Weinkauf B; Weidinger G; Stenglein S; Wahn U;
Allergy; 2004 Sep; 59(9):973-9. PubMed ID: 15291906
[TBL] [Abstract][Full Text] [Related]
6. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis.
Bez C; Schubert R; Kopp M; Ersfeld Y; Rosewich M; Kuehr J; Kamin W; Berg AV; Wahu U; Zielen S
Clin Exp Allergy; 2004 Jul; 34(7):1079-85. PubMed ID: 15248853
[TBL] [Abstract][Full Text] [Related]
7. The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis.
Stock P; Rolinck-Werninghaus C; Wahn U; Hamelmann E
BioDrugs; 2007; 21(6):403-10. PubMed ID: 18020623
[TBL] [Abstract][Full Text] [Related]
8. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy.
Kopp MV; Hamelmann E; Bendiks M; Zielen S; Kamin W; Bergmann KC; Klein C; Wahn U;
Pediatr Allergy Immunol; 2013 Aug; 24(5):427-33. PubMed ID: 23799935
[TBL] [Abstract][Full Text] [Related]
9. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects.
Winther L; Malling HJ; Mosbech H
Allergy; 2000 Sep; 55(9):827-35. PubMed ID: 11003446
[TBL] [Abstract][Full Text] [Related]
10. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
[TBL] [Abstract][Full Text] [Related]
11. A pre-seasonal birch/hazel sublingual immunotherapy can improve the outcome of grass pollen injective treatment in bisensitized individuals. A case-referent, two-year controlled study.
Cirla AM; Cirla PE; Parmiani S; Pecora S
Allergol Immunopathol (Madr); 2003; 31(1):31-43. PubMed ID: 12573207
[TBL] [Abstract][Full Text] [Related]
12. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.
Chaker AM; Shamji MH; Dumitru FA; Calderon MA; Scadding GW; Makatsori M; Jones I; He QA; Subramanian KK; Arm JP; Durham SR; Schmidt-Weber CB
J Allergy Clin Immunol; 2016 Feb; 137(2):452-461.e9. PubMed ID: 26531865
[TBL] [Abstract][Full Text] [Related]
13. Etiopathogenesis and management of perennial allergic rhinitis: a state-of-the-art review.
Bush RK
Treat Respir Med; 2004; 3(1):45-57. PubMed ID: 15174893
[TBL] [Abstract][Full Text] [Related]
14. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
[TBL] [Abstract][Full Text] [Related]
15. Depigmented-polymerized mixed grass/birch pollen extract immunotherapy is effective in polysensitized patients.
Pfaar O; Biedermann T; Klimek L; Sager A; Robinson DS
Allergy; 2013 Oct; 68(10):1306-13. PubMed ID: 23991896
[TBL] [Abstract][Full Text] [Related]
16. Specific IgE serum concentration is associated with symptom severity in children with seasonal allergic rhinitis.
Rolinck-Werninghaus C; Keil T; Kopp M; Zielen S; Schauer U; von Berg A; Wahn U; Hamelmann E;
Allergy; 2008 Oct; 63(10):1339-44. PubMed ID: 18782113
[TBL] [Abstract][Full Text] [Related]
17. Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen-induced allergic rhinoconjunctivitis in an environmental exposure unit.
Ellis AK; Tenn MW; Steacy LM; Adams DE; Day AG; Walker TJ; Nolte H
Ann Allergy Asthma Immunol; 2018 May; 120(5):495-503.e2. PubMed ID: 29432967
[TBL] [Abstract][Full Text] [Related]
18. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.
Casale TB; Condemi J; LaForce C; Nayak A; Rowe M; Watrous M; McAlary M; Fowler-Taylor A; Racine A; Gupta N; Fick R; Della Cioppa G;
JAMA; 2001 Dec; 286(23):2956-67. PubMed ID: 11743836
[TBL] [Abstract][Full Text] [Related]
19. Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms.
Kruse K; Gerwin E; Eichel A; Shah-Hosseini K; Mösges R
J Allergy Clin Immunol Pract; 2015; 3(3):381-6. PubMed ID: 25609338
[TBL] [Abstract][Full Text] [Related]
20. Cc-chemokine eotaxin as a marker of efficacy of specific immunotherapy in patients with intermittent IgE-mediated allergic rhinoconjunctivitis.
Jahnz-Rózyk K; Targowski T; Głodzinska-Wyszogrodzka E; Płusa T
Allergy; 2003 Jul; 58(7):595-601. PubMed ID: 12823117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
